<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838214</url>
  </required_header>
  <id_info>
    <org_study_id>BUC-38/AIH</org_study_id>
    <nct_id>NCT00838214</nct_id>
  </id_info>
  <brief_title>Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis</brief_title>
  <official_title>Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-Blind, Randomized, Active-Controlled, Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, multinational clinical study. It comprised two consecutive segments (A
      and B). Segment A was designed as a randomized, double-blind, double-dummy,
      active-controlled, two-arm parallel-group study. The patients received either budesonide or
      prednisone for 6 months. During segment B all patients received budesonide as an open
      treatment for additional 6 months.

      In this confirmatory study the proportion of patients with complete response was compared
      between the two treatment groups. Complete response was defined as biochemical remission
      (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of segment
      A and lack of steroid specific side effects throughout segment A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of Segment A and lack of steroid specific side effects</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of biochemical remission</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg capsules 3x/day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg tablet, 40mg starting dose titrated to 10mg over 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>3mg capsule, 3x per day for 6 months</description>
    <arm_group_label>budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months</description>
    <arm_group_label>prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 10 to 70 years

          -  Diagnosis of acute AIH according to Alvarez score

          -  normal range of TPMT activity

          -  normal ACTH test

          -  negative pregnancy test at screening for females of childbearing potential

          -  written informed consent

        Exclusion Criteria:

          -  presence of Hepatitis A, B, C, E or G virus infection

          -  liver cirrhosis or clinical signs of portal hypertension

          -  PBC

          -  PSC

          -  history of hypersensitivity to the study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Manns, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Markus Proels</name_title>
    <organization>Dr. Falk Pharma, Germany</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

